ReviewBrain sciences2023
Mood Stabilizers of First and Second Generation.
Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Thiazol-4-yl-Methylthio-Quinazolin-4(3H)-ones as Anticonvulsant Compounds: Chemical Design, Computational Studies, and Biological Evaluation.International journal of molecular sciences · 2026Article
- An Integrated Treatment Approach for Bipolar II Disorder: A Clinical Case Study.Journal of clinical medicine · 2025Article
- Genetic variants in GRIN2B and NTRK2 on the etiology and treatment response to valproate and lithium in patients with bipolar disorder.Pharmacological reports : PR · 2025Article
- Lamotrigine Therapy: Relation Between Treatment of Bipolar Affective Disorder and Incidence of Stevens-Johnson Syndrome-A Narrative Review of the Existing Literature.Journal of clinical medicine · 2025Review
- Lifelong Pharmacoprophylaxis in Bipolar Disorder: Holy Grail or Hollow Promise?Indian journal of psychological medicine · 2025Article
- Did the COVID-19 pandemic influence the use of psychotropic medications by university students and LGBTQIAPN+? A Brazilian multicenter study.Cadernos de saude publica · 2025Article
- Assessment of the pattern, severity, and outcomes of acute mood stabilizer drug poisoning.Toxicology research · 2024Article
- Lamotrigine: A Safe and Effective Mood Stabilizer for Bipolar Disorder in Reproductive-Age Adults.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis.Psychiatry research communications · 2024Review
- Rash caused by lurasidone in old chinese patient with bipolar disorder: case-based review.BMC psychiatry · 2024Review
- Effectiveness of ultra-long-term lithium treatment: relevant factors and case series.International journal of bipolar disorders · 2024Review
- Antiseizure Medication-Induced Alopecia: A Literature Review.Medicines (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The topic of this narrative review is mood stabilizers. First, the author's definition of mood-stabilizing drugs is provided. Second, mood-stabilizing drugs meeting this definition that have been employed until now are described. They can be classified into two generations based on the chronology of their introduction into the psychiatric armamentarium. First-generation mood stabilizers (FGMSs), such as lithium, valproates, and carbamazepine, were introduced in the 1960s and 1970s. Second-generation mood stabilizers (SGMSs) started in 1995, with a discovery of the mood-stabilizing properties of clozapine. The SGMSs include atypical antipsychotics, such as clozapine, olanzapine, quetiapine, aripiprazole, and risperidone, as well as a new anticonvulsant drug, lamotrigine. Recently, as a candidate for SGMSs, a novel antipsychotic, lurasidone, has been suggested. Several other atypical antipsychotics, anticonvulsants, and memantine showed some usefulness in the treatment and prophylaxis of bipolar disorder; however, they do not fully meet the author's criteria for mood stabilizers. The article presents clinical experiences with mood stabilizers of the first and second generations and with "insufficient" ones. Further, current suggestions for their use in preventing recurrences of bipolar mood disorder are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.